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Objective: To define the clinical and angiographic follow-up results after implantation of paclitaxel-eluting
stents (PESs) in stenotic saphenous vein grafts (SVGs).
Design: Prospective multicentre study. Comparison with a control group.
Methods: 60 consecutive patients with 65 lesions located in 65 SVGs (mean (SD) age of vein grafts 11.3
(5.7) years) treated with PES (V-Flex Plus, 2.7 mg/mm2 paclitaxel, Cook) and 60 patients with 60 SVG
lesions treated with bare metal stent (BMS) were included. Lesions had to be ,20 mm in length and in grafts
of 2.75–3.5 mm diameter. The 6 month angiographic follow-up was obtained on 51 lesions (79%) of the PES
group and on 51 lesions (85%) of the BMS group.
Results: Baseline clinical and angiographic characteristics were comparable between both groups. At
angiographic follow-up, three vein grafts in the PES group and five vein grafts in the BMS group were
occluded. In-stent late lumen loss was lower in PES than in BMS (0.61 (0.81) vs 1.06 (0.72) mm, respectively;
p = 0.021). In-stent binary restenosis rates were 12% vs 33%, respectively, (p = 0.012). Linear regression
analysis showed BMS to be the only factor with an effect on late lumen loss (p = 0.011). Target-vessel failure
rates were 18% in the PES group and 41% in the BMS group (p = 0.019), whereas major adverse cardiac
event (MACE) rates at 180 days were 15% and 37%, respectively (p = 0.014).
Conclusions: Implantation of non-polymer-based PES in SVG lesions is associated with a lower late lumen
loss and restenosis rate than those of BMS. There remains a substantial target-vessel failure rate and MACE
rate even at 6 months owing to graft occlusion or new lesions in the graft.
D
egenerative processes result in occlusion of 50% of
saphenous vein grafts (SVGs) within 10 years.1
Narrowing or occlusion of SVGs is associated with
increased morbidity and mortality.2 Implantation of bare metal
stents (BMS) in SVGs has been associated with a considerable
risk of restenosis and target-vessel failure.3 4 Drug-eluting
stents have considerably reduced the risk of restenosis when
used in native vessels.5–8 Only limited knowledge is available on
the use of drug-eluting stents for treatment of SVGs. The
mechanisms of in-stent restenosis in SVGs are similar to those
in native vessels.9 Thus, drug-eluting stents that reduce intimal
hyperplasia should lower restenosis and also the need for target
lesion revascularisation if used for treatment in SVGs.
This prospective multicentre study evaluated the efficacy of
non-polymer-based paclitaxel-eluting stents (PES) for treat-
ment of obstructed SVGs. These stents have been proved in the
European evaLUation of pacliTaxel-Eluting Stent (ELUTES)
Trial and the Asian Paclitaxel-Eluting Stent Clinical Trial
(ASPECT) to be effective in native coronary vessels.8 10 Results
were compared with those obtained with treatment of SVGs
using BMS.
METHODS
Patients and lesions
This was a prospective multicentre study including three
university-based study sites in Germany. A total of 60
consecutive patients with 65 de novo lesions located in 65
SVGs (mean (SD) age of vein grafts 11.3 (5.7) years) were
treated with non-polymer-based PES (V-Flex Plus, coated
directly with 2.7 mg/mm2 paclitaxel, using a proprietary
system of surface modification, Cook, West Lafayette,
Indiana, USA). Lesions had to be ,20 mm in length and in
SVGs of 2.75–3.5 mm diameter. A control group with implan-
tation of bare metal stents was composed of 60 consecutive
patients with 60 lesions in 60 SVGs (mean (SD) age of vein
grafts 10.1 (4.5) years) treated at the University Aachen,
Aachen, Germany, which fulfilled the same inclusion criteria
with regard to lesion length and vessel diameter. These lesions
were treated with BMS (34 lesions with Velocity Bx stents,
Cordis (Warren, New Jersey, USA) and 36 lesions with Zeta
stents, Guidant, Indianapolis, Indiana, USA) in the preceding
period between 2002 and 2004 before the use of PES. The study
was approved by the local ethical committees of the participat-
ing study centers.
Coronary intervention
Heparin was administered during the procedure according to
standard practice. Aspirin (100 mg/day) and clopidogrel
(300 mg loading dose) were started before the procedure.
After the procedure, clopidogrel (75 mg/day) was administered
for 6 months in addition to aspirin in the PES group and for
4 weeks in the BMS group. In case of predilatation, a stent
length longer than the initial balloon length was encouraged.
Stents were available in lengths of 12, 16, 20, 24 and 28 mm
and in diameters of 2.5, 3 and 3.5 mm in both groups. Stent
placement with the use of a distal protection device was
recommended and performed in 34 cases of the PES group and
in 28 cases of the control group. In the 28 patients of the PES
Abbreviations: ASPECT, Asian Paclitaxel-Eluting Stent Clinical Trial; BMS,
bare metal stent; ELUTES, European evaLUation of pacliTaxel-eluting stent;
MACE, major adverse cardiac events; MLD, minimal lumen diameter; PES,
paclitaxel-eluting stent; SVG, saphenous vein graft; TIMI, thrombolysis in
myocardial infarction; TLR, target lesion revascularisation
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group presenting with unstable angina, 18 (64%) were treated
with distal protection devices, and, in the 31 patients of the
BMS group, 16 (52%) were treated with distal protection
devices.
In-hospital and 6-month clinical follow-up
Procedural success was defined as,30% final diameter stenosis
in the treated lesion and the absence of major clinical
complications (in-hospital death, Q-wave myocardial infarction
or emergency coronary bypass surgery). All patients were
monitored for 6 months after the procedure for any major
adverse cardiac event (MACE): defined as death, myocardial
infarction, stent thrombosis, need for target lesion revascular-
isation (TLR) or target-vessel revascularisation, either percuta-
neous or surgical. Target-vessel failure was defined as need for
recurrent target-vessel revascularisation, restenosis .50% or
complete vessel occlusion.
Baseline clinical demographics, in-hospital complications
and the occurrence of death, myocardial infarction and
late recurrent coronary intervention during follow-up were
verified by independent hospital chart review and source
documentation.
Quantitative coronary angiography
Quantitative angiographic analysis was performed at the
angiographic core laboratory of the University Aachen using a
validated quantitative angiographic system (CAAS II System,
PieMedical, Maastricht, The Netherlands) with the contrast-
filled catheter as the calibration standard. Quantitative mea-
surements included reference diameter, lesion length, minimal
lumen diameter (MLD) in lesion (defined as the in-stent
segment plus proximal and distal 5 mm edge segments) and in-
stent (without adjacent edge segment) before and after the
procedure and at follow-up. Late lumen loss (defined as the
reduction in minimum lumen diameter from immediately after
the procedure to the 6-month follow-up), acute gain (defined
as the increase in minimal luminal diameter immediately after
percutaneous transluminal coronary angioplasty), net gain (the
difference between the acute gain and late lumen loss) and loss
index (the ratio of late lumen loss to acute gain) were
calculated. The lesion was described as ostial when it was
within 3 mm of the coronary ostia.
Statistical analysis
Statistical analysis was performed with the use of the SPSS
software. Categorial data were presented as frequencies and
compared with Pearson’s x2 test. Continuous data were
presented as mean (SD) and compared with the Student’s t
test or analysis of variance as adequate. The primary end point
of this study was to show an advantage for the PES group
compared with the BMS group with regard to the late lumen
loss. The sample size was calculated on the basis of an expected
late loss of 1 (0.8) mm for the BMS group and of 0.5 (0.7) mm
for the PES group with a type I error of 5% and a type II error of
20%, resulting in a sample size of 36 lesions with requested
angiographic follow-up. Multivariate analysis to identify pre-
dictors for angiographic restenosis was performed, including
diabetes mellitus, reference vessel diameter, lesion length, MLD
in lesion before intervention and the stent being a PES or a
BMS, as parameters. A p value ,0.05 was considered
significant.
RESULTS
Baseline characteristics
Clinical characteristics at baseline were similar between the two
groups (table 1).
Procedural characteristics
Stent placement was possible in all lesions of the BMS group
and in 64 lesions (98%) of the PES group. Stent length,
diameter and implantation pressure were similar between the
two groups (table 2).
There were four vessels with thrombolysis in myocardial
infarction (TIMI)2 flow after stent placement in the PES group
and two vessels with TIMI2 flow after stent placement in the BMS
group. All other vessels had TIMI3 flow after the procedure.
Angiographic results
Baseline angiographic results were similar for the two groups.
The 6-month follow-up angiography was performed on 51
lesions (79%) of the PES group and on 51 lesions (85%) of the
BMS group (table 3).
Three stents in the PES group and five stents in the BMS
group were occluded at follow-up. Patients in the PES group
showed a larger in-stent and in-lesion MLD at 6 months than
those in the BMS group. Figure 1 illustrates the cumulative
frequency distribution curves for the in-stent MLD before and
after stent implantation and at follow-up. A significantly lower
in-stent late lumen loss was observed with PES than with BMS
(0.61 (0.81) vs 1.06 (0.72) mm, respectively; p = 0.021). This
also translated into a significantly lower binary in-stent
restenosis rate in the polymer-based PES group than in the
BMS group (table 3).
Owing to three new lesions distant from the initial lesion site
in addition to restenosis, target vessel failure at 6 months was
Table 1 Baseline clinical characteristics
Non-polymer
based PES
(n = 60)
BMS
(n = 60) p Value
Mean (SD) age (years) 67 (11) 67 (7) 0.996
Men, n (%) 54 (90) 56 (93) 0.746
Prior myocardial infarction, n (%) 30 (50) 27 (45) 0.717
Diabetes mellitus, n (%) 15 (25) 17 (28) 0.845
Arterial hypertension, n (%) 52 (87) 46 (77) 0.244
Hyperlipidaemia, n (%) 53 (88) 52 (87) 1
Unstable angina, n (%) 28 (47) 31 (52) 0.864
Mean (SD) number of CABG 3.3 (0.9) 3.4 (0.7) 0.511
Mean (SD) age of CABG (years) 11.3 (5.7) 10.1 (4.5) 0.266
BMS, bare metal stent; CABG, coronary artery bypass graft; PES, paclitaxel-
eluting stent.
Arterial hypertension: arterial pressure .160/90 mm Hg or medically
treated.
Hyperlipidaemia: serum cholesterol .240 mg/l or medically treated.
Table 2 Baseline lesion and procedural characteristics
Non-polymer
based PES
(n = 65)
BMS
(n = 60) p Value
Location of lesion, n (%) 0.767
Ostial 12 (18) 13 (22)
Proximal 20 (31) 14 (23)
Mid 18 (28) 16 (27)
Distal and anastomotic 15 (23) 17 (28)
Distal protection devices, n (%) 34 (52) 28 (47) 0.656
No reflow 0 0 1
Mean (SD) number of stents per lesion 1.13 (0.33) 1.08 (0.28) 0.441
Mean (SD) length of stent (mm) 16.7 (3.7) 14.6 (4.4) 0.078
Mean (SD) maximal balloon diameter
(mm)
3.3 (0.3) 3.4 (0.6) 0.728
Mean (SD) maximal implantation
pressure (atm)
12 (2) 11 (3) 0.524
BMS, bare metal stent; PES, paclitaxel-eluting stent.
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seen in 9 (18%) vessels of the PES group and in 21 (41%)
vessels of the BMS group (p = 0.019).
Predictors of binary restenosis
In a multivariate model, independent predictors of binary
restenosis were the type of stent being a BMS (odds ratio (OR)
= 5.21, 95% confidence interval (CI) 1.22 to 22.2; p = 0.027),
and the minimal lumen diameter before stent placement (OR
= 0.17, 95% CI 0.04 to 0.76; p = 0.02). In a linear regression
analysis, stent being a BMS was found to be the only parameter
with an effect on late lumen loss (p = 0.011).
Clinical follow-up results
At the 30-day follow-up, a MACE rate of 0% was observed in
both study groups. No cases of stent thrombosis were noted
during the 6-month follow-up period.
At the 6-month follow-up, TLR was performed in 4 (6%)
lesions of the PES group and in 13 (22%) lesions of the BMS
group (p = 0.024). MACE at 6 months was observed in 9 of the
60 (15%) patients with PES. In the BMS group, the MACE rate
was higher at 37% (22 of 60) patients (p = 0.014) (fig 2).
DISCUSSION
Use of drug-eluting stents in SVGs has not been extensively
evaluated so far. This study shows1 improved angiographic and
clinical follow-up results after treatment of stenotic SVGs with
PES as compared with treatment using BMS,2 still a substantial
rate of target-vessel failure and MACE after treatment of
stenotic SVGs using PES owing to new lesions in the SVG.
Treatment of stenotic SVGs
Interventional treatment of obstructive vein graft disease is
associated with a high risk of procedural and follow-up
treatment failures. The increased peri-procedural risks in these
patients is related to the nature of degenerated vein graft
lesions with potential distal atheroembolisation resulting in
microvascular obstruction. The high risk of follow-up treatment
failure in SVGs compared with native coronary vessels is related
to an increased risk of restenosis at the target site and
progression of disease at other sites of the vein grafts causing
target vessel failure. The risk of distal embolisation has been
markedly reduced with the use of distal protection devices.11 12
The risk of restenosis could be reduced with the use of BMS as
compared with the use of balloon angioplasty and has become
the default interventional modality in SVGs.3 4 However, even
with the use of BMSs, at least 30–40% of SVGs fail over the next
12–18 months owing to restenosis in half of the cases and
progression of subclinical atherosclerotic disease elsewhere
than the original stented lesion in the other half.3 In this study,
late lumen loss and restenosis rate in the BMS group were
comparable to these results. In an attempt to reduce distal
embolisation and restenosis, composite stent grafts with
polytetrafluoroethylene membrane have been used.13 14
However, on the basis of available data from the STents In
GraftsTrial and Randomized Evaluation of polytetrafluoroethy-
lene COVERed stent in saphenous vein grafts trial, stent grafts
do not deliver any benefit over BMS with regard to follow-up
results. The mechanism of in-stent restenosis in vein grafts is
also neointimal hyperplasia and the response of in-stent
restenosis to brachytherapy is as effective as that to native
vessels.9 15 Thus, the benefit from antiproliferative drug-eluting
stents should be similar to that seen in native vessels. Data on
the use of drug-eluting stents in vein grafts are limited to non-
randomised studies with control groups having different
baseline characteristics.16–19 Ge et al16 reported on the use of
sirolimus-eluting stents in 35 patients and PES in 26 patients
for treatment of vein graft lesions. The restenosis rate was
shown to be 10% for this combined drug-eluting stent group,
which was markedly lower than for a control group treated in
the preceding time period with BMSs. This result was seen
despite a considerably larger reference vessel and stent
diameters in the BMS group than in the drug-eluting stent
group. In addition, the MACE free survival rate was higher in
the drug-eluting stent group than in the control group.
Paclitaxel has been shown to suppress vascular cell prolifera-
tion and subsequent excessive formation of intimal hyper-
plasia.7 8 Randomised clinical trials on the use of polymer-based
Table 3 Quantitative angiographic results
Non-polymer
based PES
(number of
lesions = 51)
BMS (number
of lesions = 51)
p
Value
Preintervention
Lesion length (mm) 11.8 (4.1) 10.8 (3.8) 0.231
Reference lumen diameter
(mm)
3.05 (0.52) 3.06 (0.60) 0.775
Minimal lumen diameter
(mm)
0.91 (0.4) 1.07 (0.52) 0.012
Diameter stenosis (%) 70 (12) 63 (11) 0.007
Postintervention
Minimal lumen diameter in
stent (mm)
2.89 (0.40) 2.8 (0.46) 0.309
Minimal lumen diameter in
lesion (mm)
2.85 (0.41) 2.77 (0.45) 0.312
Diameter stenosis in stent (%) 6 (10) 9 (8) 0.956
Diameter stenosis in lesion (%) 6 (10) 9 (8) 0.934
Follow-up
Reference lumen diameter
(mm)
3.01 (0.51) 2.96 (0.45) 0.386
Minimal lumen diameter in
stent (mm)
2.28 (0.72) 1.71 (0.62) 0.001
Minimal lumen diameter in
lesion (mm)
2.22 (0.72) 1.7 (0.65) 0.001
Diameter stenosis in stent (%) 25 (24) 42 (26) 0.003
Diameter stenosis in lesion (%) 26 (24) 43 (27) 0.003
Late loss in stent (mm) 0.61 (0.81) 1.06 (0.72) 0.021
Late loss in lesion (mm) 0.63 (0.79) 1.05 (0.75) 0.023
Loss index in stent (mm) 0.34 (0.44) 0.66 (0.62) 0.002
Binary restenosis in stent, n (%) 6 (12) 17 (33) 0.012
BMS, bare metal stent; PES, paclitaxel-eluting stents.
Values are mean (SD) unless otherwise specified.
Figure 1 Cumulative frequency distribution curves for in-stent minimal
lumen diameter for both study groups before stent placement, after stent
placement and at follow-up (FU). The dotted lines relate to the non-
polymer-based paclitaxel-eluting stent group and the solid lines relate to
the bare metal stent group.
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PES in native coronary lesions have shown remarkable and
consistent effectiveness of polymer-based PES in the reduction
of in-stent restenosis and repeat TLR.7 Non-polymer-based drug
delivery has been suggested as a different approach to deliver
paclitaxel, which circumvents the potential limitations of a
polymer coating such as local hypersensitivity to the polymer
with subsequent excessive inflammation. The multicentre
ASPECT ELUTES, and DELIVER I (the RX Achieve drug-eluting
coronary stent system in the treatment of patients with de novo
native coronary lesions) evaluated PES without polymer coat-
ing for treatment of de novo native coronary lesions.8 10 20 A
significant reduction of neointimal hyperplasia and restenosis
were observed in the high-dose groups of the ASPECT and
ELUTES Trials.
Treatment using paclitaxel-eluting stents in this study
This study showed a significant advantage of using non-
polymer-based PES in the treatment of obstructed vein grafts
compared with BMS with regard to late lumen loss, restenosis
rate and clinical events. Thus, the study supports the use of
drug-eluting stents for obstructed SVG. Recent data have
indicated that sirolimus-eluting stents may be more effective to
lower late lumen loss and restenosis than polymer-based PES.
Furthermore, on the basis of data from the DELIVER I and II
Trials, the effectiveness of the non-polymer-based PES to
reduce restenosis seems less reliable than for polymer-based
PES. Thus, further studies will be required to define whether
stents with sirolimus coating may be even more effective to
suppress restenosis and recurrent target lesion revascularisation
in SVGs than shown in this study.
Study limitations
This was not a randomised study. Patients were enrolled to the
two study groups in a sequential manner. However, to our
knowledge this is the first multicentre study with equal clinical
and angiographic baseline characteristics, which used only one
drug-eluting stent type and involved a high angiographic
follow-up rate. The study inclusion criteria requested vein graft
diameters of (3.5 mm. This was because of the non-
availability of the evaluated PES in diameters .3.5 mm.
Thus, large vein graft diameters were excluded from this study.
From studies on native vessels, it is known that the risk of
restenosis reduces with increasing size of the vessel.21 22 Thus,
the advantage of drug-eluting stents may be smaller in vein
grafts of greater diameter.
CONCLUSION
Implantation of non-polymer-based paclitaxel-eluting stents in
new SVG lesions is associated with a lower late loss, restenosis
rate and target lesion revascularisation rate than those of BMS.
However, there remains a substantial target-vessel failure rate
and MACE rate even at 6 months owing to graft occlusion or
new lesions in the graft.
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